LEADERSHIP

Cameron Black

VP, Discovery

Cameron joined Repare Therapeutics in mid-2016 to lead the drug discovery efforts on newly identified synthetic lethal targets. Prior to this, he spent 18 years at Merck Frosst during which time he was responsible for the identification of seven drug candidates. He led both the discovery and early clinical development of the cathepsin K inhibitor odanacatib, a once-weekly treatment for osteoporosis.

+ Show More

Lloyd M. Segal

President & CEO

Lloyd is an Entrepreneur-in-residence at Versant Ventures, and from 2010-2016 was a Managing Partner at Persistence Capital Partners, a leading Healthcare private equity investor. He held CEO roles at Caprion Pharmaceticals, which he co-founded, Advanced Bioconcept and Thallion Pharmaceuticals, and has served as a director of several public and private corporations in the U.S. and Canada.

+ Show More

Kim Seth

EVP, Business & Corporate Development

Kim is Executive Vice President of Business & Corporate Development. Prior to joining Repare, he was Chief Business Officer and Chief Operating Officer at Resilience Therapeutics and CBO/SVP of Corporate Development & Strategy at Epirus Biopharmaceuticals.

+ Show More

Michael Zinda

EVP, Head of R&D

Michael is the Executive Vice President, Head of Research and Development at Repare Therapeutics. Prior to joining Repare, he led the oncology bioscience organization at AstraZeneca R&D Boston. In this role he served on the global science leadership team, oncology research board and the Acerta research and early development teams accountable for strategy, key collaborations/partnerships and delivery of an innovative portfolio of patient centric drug discovery programs.

+ Show More